Hematologic Malignancies
News
Adding venetoclax improves ibrutinib outcomes in CLL
A small study yields sanguine news about a combination treatment, as hematologists await phase 3 results.
News
Off their pricey CML meds, many thrive
For CML patients in remission, specialists suggest trying drug omission – which often yields good outcomes and a reprieve from side effects.
News
Multiple myeloma diagnosed more via emergency care during COVID
While trying to avoid COVID-19 infection, patients ultimately diagnosed with multiple myeloma may have delayed interactions with healthcare...
News
High cost and demand for old cancer drug sparks crisis
Experts have voiced alarm at the scarcity and cost of fludarabine, an old drug deemed crucial to cellular therapy for leukemia.
News
Pandemic caused treatment delay for half of patients with CTCL, study finds
No clinical trials exist to inform maintenance protocols in patients with cutaneous lymphomas.
News
Blenrep for multiple myeloma withdrawn from U.S. market
As requested by the U.S. Food and Drug Administration, the multiple myeloma drug blenrep is being taken off the market after disappointing results...
News
CAR T-cell therapy neurotoxicity linked to NfL elevations
Even prior to CAR T-cell therapy, patients developing related neurotoxic complications show elevated markers of neuronal injury.
News
Drug combo holds promise of better AML outcomes
Study suggests that the venetoclax-gilteritinib drug combination “potentially improves response frequency and depth.”